Curb your enthusiasm: tramadol prescribed at discharge.

Reg Anesth Pain Med

Department of Anesthesia and Pain Management, Centro Nacional de Rehabilitacion, Hospital del Trauma, San Jose, Costa Rica

Published: July 2022

Download full-text PDF

Source
http://dx.doi.org/10.1136/rapm-2022-103898DOI Listing

Publication Analysis

Top Keywords

curb enthusiasm
4
enthusiasm tramadol
4
tramadol prescribed
4
prescribed discharge
4
curb
1
tramadol
1
prescribed
1
discharge
1

Similar Publications

Dexmedetomidine in paediatric anaesthesia: a call for action?

Br J Anaesth

August 2024

Department of Anesthesiology, Pharmacology, Intensive Care, and Emergency Medicine, University Hospitals of Geneva, Geneva, Switzerland; Geneva Neuroscience Center, University of Geneva, Geneva, Switzerland. Electronic address:

Dexmedetomidine is increasingly used in paediatric anaesthesia practice. In this issue of the British Journal of Anaesthesia, a retrospective hospital registry study in anaesthetised children showed that intraoperative use of dexmedetomidine was dose-dependently associated with a longer postanaesthesia care unit length of stay. Dexmedetomidine administration was also associated with higher total hospital costs and higher odds of unwarranted haemodynamic effects, while the onset of emergence delirium was not reduced.

View Article and Find Full Text PDF

Early Antibiotics in Septic Shock: A Desirable Goal but "Curb Your Enthusiasm".

Indian J Crit Care Med

July 2023

Department of Critical Care and Medicine, P.D. Hinduja Hospital, Mumbai, Maharashtra, India.

: Hegde A. Early Antibiotics in Septic Shock: A Desirable Goal but "Curb Your Enthusiasm". Indian J Crit Care Med 2023;27(7):459-460.

View Article and Find Full Text PDF

Glycyrrhizin for treatment of CRS caused by CAR T-cell therapy: A pharmacological perspective.

Front Pharmacol

February 2023

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Chimeric antigen receptor T (CAR T)-cell therapy promises to revolutionize the management of hematologic malignancies and possibly other tumors. However, the main side effect of cytokine release syndrome (CRS) is a great challenge for its clinical application. Currently, treatment of CRS caused by CAR T-cell therapy is limited to tocilizumab (TCZ) and corticosteroids in clinical guidelines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!